Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6天前
Aclaris Therapeutics Q1 EPS $(0.31) Up From $(0.57) YoY, Sales $1.45M Down From $1.78M YoY
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.31) per share. This is a 45.61 percent increase over losses of $(0.57) per share from the same period last year. The company reported $1.45 million in
Benzinga · 6天前
BRIEF-Aclaris Therapeutics Reports First Quarter 2022 Financial Results And Provides A Corporate Update
reuters.com · 6天前
Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09, revenue of $1.45M misses by $0.22M
Aclaris Therapeutics press release (NASDAQ:ACRS): Q1 GAAP EPS of -$0.31 beats by $0.09. Revenue of $1.45M (-18.5% Y/Y) misses by $0.22M.